Cost–effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain
Aim: To analyze the cost–effectiveness of treatment of relapsing remitting multiple sclerosis (RRMS) with cladribine tablets (CladT) and dimethyl fumarate (DMF) from the perspective of the Spanish National Health System (NHS). Methods: A probabilistic Markov model (second-order Monte Carlo simulat...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Becaris Publishing Limited
2023-01-01
|
| Series: | Journal of Comparative Effectiveness Research |
| Subjects: |
| _version_ | 1827905896882110464 |
|---|---|
| author | Ricardo Ginestal Carlos Rubio-Terres Olga Duran Moran Dario Rubio-Rodriguez Heidi De Los Santos Cristina Ordonez Isabel Sanchez-Magro |
| author_facet | Ricardo Ginestal Carlos Rubio-Terres Olga Duran Moran Dario Rubio-Rodriguez Heidi De Los Santos Cristina Ordonez Isabel Sanchez-Magro |
| author_sort | Ricardo Ginestal |
| collection | DOAJ |
| description | Aim: To analyze the cost–effectiveness of treatment of relapsing remitting multiple sclerosis (RRMS) with
cladribine tablets (CladT) and dimethyl fumarate (DMF) from the perspective of the Spanish National
Health System (NHS). Methods: A probabilistic Markov model (second-order Monte Carlo simulation)
with a 10-year time horizon and annual Markov cycles was performed. Results: CladT was the dominant
treatment, with lower costs (-74,741 € [95% CI: -67,247; -85,661 €]) and greater effectiveness (0.1920 [95%
CI: -0.1659; 0.2173] QALY) per patient, compared with DMF. CladT had a 95.1% probability of being costeffective
and a 94.1% chance of being dominant compared with DMF. Conclusion: CladT is the dominant
treatment (lower costs, with more QALYs) compared with DMF in the treatment of RRMS in Spain. |
| first_indexed | 2024-03-13T00:48:24Z |
| format | Article |
| id | doaj.art-67797726f32d4ae5990dafe8032544fb |
| institution | Directory Open Access Journal |
| issn | 2042-6313 |
| language | English |
| last_indexed | 2024-03-13T00:48:24Z |
| publishDate | 2023-01-01 |
| publisher | Becaris Publishing Limited |
| record_format | Article |
| series | Journal of Comparative Effectiveness Research |
| spelling | doaj.art-67797726f32d4ae5990dafe8032544fb2023-07-08T12:31:31ZengBecaris Publishing LimitedJournal of Comparative Effectiveness Research2042-63132023-01-0112210.2217/cer-2022-0193Cost–effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in SpainRicardo Ginestal0Carlos Rubio-Terres1Olga Duran Moran2Dario Rubio-Rodriguez3Heidi De Los Santos4Cristina Ordonez5Isabel Sanchez-Magro6Hospital Clinico San Carlos, Neurology Department, C/ Prof Martin Lagos, 28040 Madrid, SpainHEALTH VALUE, HE Department, C/ Virgen de Aranzazu, 21, 28034 Madrid, SpainMerck, SLU, C/ Maria de Molina, 40, 28006 Madrid, Spain, an affiliate of Merck KGaAHEALTH VALUE, HE Department, C/ Virgen de Aranzazu, 21, 28034 Madrid, SpainMerck, SLU, C/ Maria de Molina, 40, 28006 Madrid, Spain, an affiliate of Merck KGaAMerck, SLU, C/ Maria de Molina, 40, 28006 Madrid, Spain, an affiliate of Merck KGaAMerck, SLU, C/ Maria de Molina, 40, 28006 Madrid, Spain, an affiliate of Merck KGaAAim: To analyze the cost–effectiveness of treatment of relapsing remitting multiple sclerosis (RRMS) with cladribine tablets (CladT) and dimethyl fumarate (DMF) from the perspective of the Spanish National Health System (NHS). Methods: A probabilistic Markov model (second-order Monte Carlo simulation) with a 10-year time horizon and annual Markov cycles was performed. Results: CladT was the dominant treatment, with lower costs (-74,741 € [95% CI: -67,247; -85,661 €]) and greater effectiveness (0.1920 [95% CI: -0.1659; 0.2173] QALY) per patient, compared with DMF. CladT had a 95.1% probability of being costeffective and a 94.1% chance of being dominant compared with DMF. Conclusion: CladT is the dominant treatment (lower costs, with more QALYs) compared with DMF in the treatment of RRMS in Spain.cladribine tabletscost–effectivenessdimethyl fumaratemultiple sclerosisrelapsing-remitting multiple sclerosis |
| spellingShingle | Ricardo Ginestal Carlos Rubio-Terres Olga Duran Moran Dario Rubio-Rodriguez Heidi De Los Santos Cristina Ordonez Isabel Sanchez-Magro Cost–effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain Journal of Comparative Effectiveness Research cladribine tablets cost–effectiveness dimethyl fumarate multiple sclerosis relapsing-remitting multiple sclerosis |
| title | Cost–effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain |
| title_full | Cost–effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain |
| title_fullStr | Cost–effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain |
| title_full_unstemmed | Cost–effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain |
| title_short | Cost–effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain |
| title_sort | cost effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in spain |
| topic | cladribine tablets cost–effectiveness dimethyl fumarate multiple sclerosis relapsing-remitting multiple sclerosis |
| work_keys_str_mv | AT ricardoginestal costeffectivenessofcladribinetabletsanddimethylfumarateinthetreatmentofrelapsingremittingmultiplesclerosisinspain AT carlosrubioterres costeffectivenessofcladribinetabletsanddimethylfumarateinthetreatmentofrelapsingremittingmultiplesclerosisinspain AT olgaduranmoran costeffectivenessofcladribinetabletsanddimethylfumarateinthetreatmentofrelapsingremittingmultiplesclerosisinspain AT dariorubiorodriguez costeffectivenessofcladribinetabletsanddimethylfumarateinthetreatmentofrelapsingremittingmultiplesclerosisinspain AT heididelossantos costeffectivenessofcladribinetabletsanddimethylfumarateinthetreatmentofrelapsingremittingmultiplesclerosisinspain AT cristinaordonez costeffectivenessofcladribinetabletsanddimethylfumarateinthetreatmentofrelapsingremittingmultiplesclerosisinspain AT isabelsanchezmagro costeffectivenessofcladribinetabletsanddimethylfumarateinthetreatmentofrelapsingremittingmultiplesclerosisinspain |